MX2018003350A - Nanoparticulas no vesiculares altamente estables y aplicacion de las mismas para tratar infecciones microbianas. - Google Patents

Nanoparticulas no vesiculares altamente estables y aplicacion de las mismas para tratar infecciones microbianas.

Info

Publication number
MX2018003350A
MX2018003350A MX2018003350A MX2018003350A MX2018003350A MX 2018003350 A MX2018003350 A MX 2018003350A MX 2018003350 A MX2018003350 A MX 2018003350A MX 2018003350 A MX2018003350 A MX 2018003350A MX 2018003350 A MX2018003350 A MX 2018003350A
Authority
MX
Mexico
Prior art keywords
application
highly stable
microbial infection
stable non
treating microbial
Prior art date
Application number
MX2018003350A
Other languages
English (en)
Inventor
Wang Gang
Tan Yun
Original Assignee
Alaya Shanghai Bioscience Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alaya Shanghai Bioscience Co Ltd filed Critical Alaya Shanghai Bioscience Co Ltd
Publication of MX2018003350A publication Critical patent/MX2018003350A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Nanopartículas no vesiculares que tienen actividad antibacteriana y están hechas de un ácido graso C8-C28 o un derivado del mismo, un tensioactivo y un lípido opcional.
MX2018003350A 2015-09-17 2016-09-14 Nanoparticulas no vesiculares altamente estables y aplicacion de las mismas para tratar infecciones microbianas. MX2018003350A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510594983.0A CN106551902B (zh) 2015-09-17 2015-09-17 一种高稳定的非囊泡型纳米颗粒及其在治疗微生物感染中的应用
PCT/CN2016/099136 WO2017045628A1 (zh) 2015-09-17 2016-09-14 一种高稳定的非囊泡型纳米颗粒及其在治疗微生物感染中的应用

Publications (1)

Publication Number Publication Date
MX2018003350A true MX2018003350A (es) 2019-05-30

Family

ID=58288035

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003350A MX2018003350A (es) 2015-09-17 2016-09-14 Nanoparticulas no vesiculares altamente estables y aplicacion de las mismas para tratar infecciones microbianas.

Country Status (13)

Country Link
US (1) US11266604B2 (es)
EP (1) EP3351238A4 (es)
JP (1) JP7048496B2 (es)
KR (1) KR20180066103A (es)
CN (2) CN106551902B (es)
AU (1) AU2016321503B2 (es)
BR (1) BR112018005268A2 (es)
CA (1) CA2998913A1 (es)
IL (1) IL258169B (es)
MX (1) MX2018003350A (es)
RU (1) RU2733320C2 (es)
WO (1) WO2017045628A1 (es)
ZA (1) ZA201802537B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102349267B1 (ko) * 2020-05-20 2022-01-10 영남대학교 산학협력단 미리스톨레익산을 유효성분으로 함유하는 항균 및 생물막 형성 억제용 조성물
CN112666054B (zh) * 2020-12-29 2024-08-23 四川普锐特药业有限公司 吸入用布地奈德混悬液中布地奈德粒径的测定方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3421468A1 (de) * 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
US5250236A (en) * 1991-08-05 1993-10-05 Gasco Maria R Method for producing solid lipid microspheres having a narrow size distribution
EP1498123A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Emulsifying systems containing azetidine derivatives
CN103315954A (zh) * 2005-07-18 2013-09-25 麻萨诸塞州洛厄尔大学 制备与使用纳米乳剂的组合物和方法
JP2009533341A (ja) 2006-04-07 2009-09-17 ノババックス，インコーポレイテッド 抗細菌、抗真菌、抗酵母、および／または抗ウイルス特性を有するナノ構造組成物
US20110028546A1 (en) 2006-08-06 2011-02-03 Belle Kumar Novel antimicrobial formulations incorporating alkyl esters of fatty acids and nanoemulsions thereof
WO2009067734A1 (en) * 2007-11-28 2009-06-04 Commonwealth Scientific And Industrial Research Organisation Nanoemulsions
CN101530390A (zh) * 2008-03-14 2009-09-16 西安中基高技术产业发展有限公司 α-亚麻酸纳米脂质体制剂的制备与处方
WO2010045292A2 (en) * 2008-10-15 2010-04-22 The University Of North Carolina At Chapel Hill Nanoparticle compositions comprising liquid oil cores
CN101385714B (zh) 2008-10-24 2011-07-27 苏州纳康生物科技有限公司 Dha脂质纳米粒的制备方法
CN102639129B (zh) * 2009-11-17 2016-08-24 迈克尔·A·福兰 含游离脂肪酸的抗微生物组合物
ES2415804T3 (es) * 2010-03-23 2013-07-29 Cognis Ip Management Gmbh Composición para lavar platos manualmente, suave con la piel
CN102048696B (zh) * 2011-01-13 2013-08-07 南昌大学 一种脂质纳米粒的制备方法
JP6030630B2 (ja) * 2011-04-14 2016-11-24 ノヴォ ノルディスク アー／エス 経口ペプチド送達のための脂肪酸アシル化アミノ酸
RU2480203C2 (ru) 2011-04-22 2013-04-27 Общество с ограниченной ответственностью "Нанобиотех" Антибактериальная композиция и способ ее получения
JP5872838B2 (ja) * 2011-10-19 2016-03-01 太陽化学株式会社 抗菌組成物
GB201215289D0 (en) * 2012-08-28 2012-10-10 Medical Res Council Nanoparticle formulation
WO2014140268A1 (en) 2013-03-15 2014-09-18 Dsm Ip Assets B. V. Solid lipid nanoparticles (ii)
CN103551090A (zh) * 2013-11-08 2014-02-05 江南大学 一种直接分散法制备卵磷脂/非离子表面活性剂混合胶束方法

Also Published As

Publication number Publication date
WO2017045628A1 (zh) 2017-03-23
CN111759823A (zh) 2020-10-13
EP3351238A4 (en) 2019-07-10
JP7048496B2 (ja) 2022-04-05
CN111759823B (zh) 2022-12-30
AU2016321503B2 (en) 2022-04-14
EP3351238A1 (en) 2018-07-25
BR112018005268A2 (pt) 2018-10-09
KR20180066103A (ko) 2018-06-18
AU2016321503A1 (en) 2018-05-10
ZA201802537B (en) 2019-07-31
US20180250228A1 (en) 2018-09-06
RU2018109992A3 (es) 2019-11-14
CA2998913A1 (en) 2017-03-23
IL258169A (en) 2018-05-31
JP2018532770A (ja) 2018-11-08
IL258169B (en) 2021-06-30
CN106551902B (zh) 2020-07-03
RU2733320C2 (ru) 2020-10-01
CN106551902A (zh) 2017-04-05
RU2018109992A (ru) 2019-10-17
US11266604B2 (en) 2022-03-08

Similar Documents

Publication Publication Date Title
MD3209310T2 (ro) Compoziții care conțin tulpini bacteriene
MD3209381T2 (ro) Compoziții care conțin tulpini bacteriene
MX2017007829A (es) Composicion antimicrobiana.
MY195009A (en) Cellular Targeted Active Ingredient Delivery System
MX2018008190A (es) Sistemas y metodos para la administracion transdermica a largo plazo.
PH12017501646A1 (en) Antimicrobial compounds and methods of making and using the same
EP3273079A4 (en) Electromagnetically enabled active type dynamic gas bearing
MY173518A (en) Antimicrobial compounds and methods of making and using the same
PH12016500453A1 (en) Antimicrobial compounds and methods of making and using the same
EP4241844A3 (en) Compositions for topical treatment of microbial infections
MX370628B (es) Composiciones y metodos para tratar las espinillas.
MX2018001512A (es) Composiciones antimicrobianas que comprenden mupirocina y neomicina.
MX2015008486A (es) Composiciones y metodos para tratar infecciones bacterianas.
IL269546A (en) Lactic acid bacteria, methods and uses thereof
MA39955A (fr) Compositions désinfectantes et antimicrobiennes, en particulier pour le domaine vétérinaire
MX2018003350A (es) Nanoparticulas no vesiculares altamente estables y aplicacion de las mismas para tratar infecciones microbianas.
EP3443975A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HEARING LOSS COMPRISING OATOUS EXTRACT AS ACTIVE INGREDIENT
WO2017161344A8 (en) Compositions and methods for treating parasitic diseases
PH12019502145A1 (en) Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient
UY34189A (es) Mezclas fungicidas que comprenden isoxazol y otro ingrediente activo.
HUE059185T2 (hu) Készítmény, amely e vitaminon vagy észteren alapul bakteriális vagy gomba eredetû biofilmek kezelésére
MX2017009213A (es) Compuestos basados en nisina y su uso en el tratamiento de infecciones bacterianas.
SG10201810362SA (en) Anti-allergic agent, agent for improving allergic diarrhea and pharmaceutical composition
PH12016000259B1 (en) Antibacterial ointment for staphylococcus aureus infections
BR112017021044A2 (pt) agente terapêutico para o olho seco compreendendo nandrolona ou éster da mesma ou metenolona ou éster da mesma como um ingrediente ativo